Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.
The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2021’s virtual meeting of industry leaders, investors and technology creators.
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
A selection of articles you might have missed from November and December 2020, including exclusive interviews with industry leaders and a deeper dive into COVID-19's impact on R&D.
Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
Coronavirus has definitively changed health care delivery and the perceptions of health technologies and digital ecosystems. Industry will need to adjust to the aftermath of COVID-19, take opportunities and learn lessons from 2020 or 2021 could be every inch as challenging.
2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Supply chain expert outlines to In Vivo how pharma can create resilient and secure supply chains and some benefits of localization.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.